MBX (MBX Biosciences) Debt-to-Equity : -0.00 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Debt-to-Equity?

MBX Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.16 Mil. MBX Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.09 Mil. MBX Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-97.89 Mil. MBX Biosciences's debt to equity for the quarter that ended in Jun. 2024 was -0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MBX Biosciences's Debt-to-Equity or its related term are showing as below:

MBX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

MBX Biosciences Debt-to-Equity Historical Data

The historical data trend for MBX Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Debt-to-Equity Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Debt-to-Equity

-0.01

MBX Biosciences Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	-0.01	N/A	-	-

Competitive Comparison of MBX Biosciences's Debt-to-Equity

For the Biotechnology subindustry, MBX Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Debt-to-Equity falls into.

MBX Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MBX Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.153	+	0.171)	/	-72.468
	=	-0.00

MBX Biosciences's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.162	+	0.087)	/	-97.885
	=	-0.00

MBX Biosciences (NAS:MBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MBX Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.